$HIMS
Hims & Hers Health, Inc.

2020 Q1 Form 10-Q Financial Statement

#000119312520141765 Filed on May 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q1
Revenue $30.06M
YoY Change
Cost Of Revenue $9.444M
YoY Change
Gross Profit $20.62M
YoY Change
Gross Profit Margin 68.59%
Selling, General & Admin $14.06M
YoY Change
% of Gross Profit 68.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $180.0K
YoY Change
% of Gross Profit 0.87%
Operating Expenses $26.84M
YoY Change
Operating Profit -$6.218M
YoY Change
Interest Expense $10.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $230.0K
YoY Change
Pretax Income -$5.998M
YoY Change
Income Tax $35.00K
% Of Pretax Income
Net Earnings -$6.033M
YoY Change
Net Earnings / Revenue -20.07%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17
COMMON SHARES
Basic Shares Outstanding 34.61M shares
Diluted Shares Outstanding 34.61M shares

Balance Sheet

Concept 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.500M
YoY Change
Cash & Equivalents $1.482M
Short-Term Investments
Other Short-Term Assets $100.0K
YoY Change
Inventory
Prepaid Expenses $117.4K
Receivables
Other Receivables
Total Short-Term Assets $1.599M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $204.7M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $204.7M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.599M
Total Long-Term Assets $204.7M
Total Assets $206.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $74.55K
YoY Change
Accrued Expenses $558.6K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.167M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $7.200M
YoY Change
Total Long-Term Liabilities $7.200M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.167M
Total Long-Term Liabilities $7.200M
Total Liabilities $8.361M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $2.481M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$140.0M
YoY Change
Total Liabilities & Shareholders Equity $206.3M
YoY Change

Cashflow Statement

Concept 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.033M
YoY Change
Depreciation, Depletion And Amortization $180.0K
YoY Change
Cash From Operating Activities -$5.191M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $7.233M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.34M
YoY Change
NET CHANGE
Cash From Operating Activities -$5.191M
Cash From Investing Activities $7.233M
Cash From Financing Activities $30.34M
Net Change In Cash $32.37M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$5.191M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
979394
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2518131
CY2020Q1 us-gaap Assets
Assets
206287199
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
558617
CY2019Q4 us-gaap Assets
Assets
204765183
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2481284
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5000001
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
478577
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
74554
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1167388
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18475
CY2019Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
25000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1334022
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
80040
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
56079
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206287199
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3852147
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1147262
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204765183
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
246783
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28639
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28639
CY2019Q3 oacu Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P185D
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1481702
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
117350
CY2020Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
204688147
CY2020Q1 oacu Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
84839
CY2020Q1 oacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2020Q1 oacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2020Q1 us-gaap Liabilities
Liabilities
8361138
CY2020Q1 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
192926060
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Assets Current
AssetsCurrent
1599052
CY2020Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
449378
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1510341
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
147500
CY2019Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
203107342
CY2019Q4 oacu Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
54839
CY2019Q4 oacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2019Q4 oacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2019Q4 us-gaap Liabilities
Liabilities
8173144
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
191592030
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1657841
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
427503
CY2019Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11900000
CY2019Q2 oacu Percentage Of Founder Shares On Outstanding Shares
PercentageOfFounderSharesOnOutstandingShares
0.20
oacu Common Stock Shares Resale Or Transfer Share Price Threshold
CommonStockSharesResaleOrTransferSharePriceThreshold
12.00
oacu Advances From Related Party Agreed Amount
AdvancesFromRelatedPartyAgreedAmount
300000
CY2019Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-246783
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1580805
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1580805
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-30150
CY2020Q1 oacu Increase Decrease In Accrued Expensed Related Party
IncreaseDecreaseInAccruedExpensedRelatedParty
-30000
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
21875
CY2020Q1 oacu Regulatory Withdrawal
RegulatoryWithdrawal
325000
CY2020Q1 us-gaap Cash
Cash
1500000
CY2020Q1 oacu Working Capital
WorkingCapital
432000
CY2020Q1 oacu Annual Threshold Limit Regulatory Withdrawal
AnnualThresholdLimitRegulatoryWithdrawal
325000
CY2020Q1 oacu Proceeds From Issuance Of Founder Shares
ProceedsFromIssuanceOfFounderShares
25000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 oacu Advances From Related Party
AdvancesFromRelatedParty
62000
CY2020Q1 oacu Investment Income Interest Net Of Regulatory Withdrawal
InvestmentIncomeInterestNetOfRegulatoryWithdrawal
1600000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5000009
CY2020Q1 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
-1334030
CY2019Q3 oacu Business Combination Requisites To Be Satisfied
BusinessCombinationRequisitesToBeSatisfied
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
CY2019Q3 oacu Business Combination Covenants To Proceed With Business Combination
BusinessCombinationCovenantsToProceedWithBusinessCombination
In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination.
CY2019Q3 oacu Description Of Results For Non Compliance With Business Combination
DescriptionOfResultsForNonComplianceWithBusinessCombination
The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021
CY2020Q1 oacu Working Capital Loan
WorkingCapitalLoan
0
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment.&#160;It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events.&#160;Accordingly, the actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 oacu Common Stock Conversion Description
CommonStockConversionDescription
20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity- linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Oaktree Acquisition Corp.
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001773751
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Shell Company
EntityShellCompany
true
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA

Files In Submission

Name View Source Status
0001193125-20-141765-index-headers.html Edgar Link pending
0001193125-20-141765-index.html Edgar Link pending
0001193125-20-141765.txt Edgar Link pending
0001193125-20-141765-xbrl.zip Edgar Link pending
d918745d10q.htm Edgar Link pending
d918745dex311.htm Edgar Link pending
d918745dex312.htm Edgar Link pending
d918745dex321.htm Edgar Link pending
d918745dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oacu-20200331.xml Edgar Link completed
oacu-20200331.xsd Edgar Link pending
oacu-20200331_cal.xml Edgar Link unprocessable
oacu-20200331_def.xml Edgar Link unprocessable
oacu-20200331_lab.xml Edgar Link unprocessable
oacu-20200331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending